ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$39.77
−0.53%0
Insider buys (3m)
36
Insider sells (3m)
-$224.6M
Net value (3m)
+29.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 18, 2026 | MANCHESTER KEITH S · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | Epperly Melissa B, · director | A-Award | 10,531 | $40 |
| Sep 18, 2026 | Epperly Melissa B, · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | Fitzgerald Meghan · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | MANCHESTER KEITH S · director | A-Award | 10,531 | $40 |
| Sep 18, 2026 | Gold Daniel Allen · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | MOMTAZEE JAMES C · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | Fitzgerald Meghan · director | A-Award | 10,531 | $40 |
| Sep 18, 2026 | Gold Daniel Allen · director | A-Award | 10,531 | $40 |
| Sep 18, 2026 | Oren Ilan · director | A-Award | 10,531 | $40 |
| Sep 18, 2026 | Oren Ilan · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | MOMTAZEE JAMES C · director | A-Award | 10,531 | $40 |
| Sep 17, 2026 | Fitzgerald Meghan · director | Sale | 4,712 | $40 |
| Sep 17, 2026 | Fitzgerald Meghan · director | Sale | 400 | $40 |
| Sep 17, 2026 | Epperly Melissa B, · director | Sale | 4,338 | $40 |
| Sep 17, 2026 | Epperly Melissa B, · director | Sale | 600 | $40 |
| Sep 14, 2026 | Oren Ilan · director | F-InKind | 2,378 | $41 |
| Sep 14, 2026 | Gold Daniel Allen · director | F-InKind | 5,133 | $41 |
| Sep 14, 2026 | MOMTAZEE JAMES C · director | F-InKind | 2,905 | $41 |
| Sep 14, 2026 | Fitzgerald Meghan · director | F-InKind | 1,743 | $41 |
| Sep 14, 2026 | Epperly Melissa B, · director | F-InKind | 2,179 | $41 |
| Sep 10, 2026 | Fitzgerald Meghan · director | Sale | 20,000 | $40 |
| Sep 10, 2026 | Fitzgerald Meghan · director | M-Exempt | 20,000 | $8.80 |
| Sep 1, 2026 | Venker Eric · officer: President & Immunovant CEO | M-Exempt | 200,000 | $3.85 |
| Sep 1, 2026 | Venker Eric · officer: President & Immunovant CEO | Sale | 33,818 | $36 |
| Sep 1, 2026 | Venker Eric · officer: President & Immunovant CEO | Sale | 166,182 | $36 |
| Aug 24, 2026 | Venker Eric · officer: President & Immunovant CEO | F-InKind | 13,909 | $37 |
| Aug 24, 2026 | Pulik Richard · officer: CFO | F-InKind | 5,749 | $37 |
| Aug 21, 2026 | Sukhatme Mayukh · director, officer: President & CIO | Sale | 144,756 | $36 |
| Aug 21, 2026 | Sukhatme Mayukh · director, officer: President & CIO | M-Exempt | 144,756 | $3.85 |
Institutional positioning
13F filings over the trailing two quarters
New 191Increased 375Reduced 271Sold out 43
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 81,020,390 | Aug 13, 2026 |
| FMR LLC | Increased | 77,981,253 | May 15, 2026 |
| MORGAN STANLEY | Reduced | 51,828,325 | May 15, 2026 |
| BlackRock, Inc. | Increased | 48,236,091 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 44,254,260 | May 13, 2026 |
| MORGAN STANLEY | Reduced | 42,592,905 | Aug 13, 2026 |
| QVT FINANCIAL LP | Reduced | 25,161,237 | May 15, 2026 |
| QVT Financial LP | Reduced | 23,723,074 | Aug 14, 2026 |
| UBS GROUP AG | Increased | 22,619,472 | May 5, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 22,123,198 | Aug 13, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 21,641,339 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 20,680,572 | May 15, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 19,838,698 | May 8, 2026 |
| GOLDMAN SACHS GROUP INC | Increased | 18,556,458 | Aug 14, 2026 |
| STATE STREET CORP | Increased | 17,795,975 | Aug 7, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 18, 2026